A Clinical Study on Signal Switch Receptor Modified Tumor Infiltrating Lymphocytes Injection (GC201 TIL) in Patients With Gynecologic Tumors
试验速览
- 阶段
- 早期 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Adverse Events (AE)
研究概览
简要总结
This study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified(TGF-β receptor or PD-1 gene modified TILs which could transfer the suppression signal surrounding the microenvironment of tumor bed into persistent T cell activation signal) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age: 18 years to 75 years;
- •Histologically diagnosed as primary/relapsed/metastasized Gynecological tumors;
- •Expected life-span more than 3 months;
- •Karnofsky≥60% or ECOG score 0-2;
- •Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.
- •Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated;
- •At least 1 evaluable tumor lesion;
- •Hematology and Chemistry（within 7 days prior to enrollment）:
- •Absolute count of white blood cells≥2.5×10^9/L;
- •Absolute count of neutropils≥1.5×10^9/L;
- •Absolute count of lymphocytes ≥0.7×109/L；
- •Platelet count≥100×10^9；
- •hemoglobin≥90 g/L;
- •Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);
- •International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);
- •Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min;
- •Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN);
- •Totol bilirubin≤1.5×ULN;
- •no absolute or relative contraindications to operation or biopsy;
- •Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 1 year after the completion of lymphodepletion；
- •Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy and biologics must cease 28 days before obtaining TILs;
- •Be able to understand and sign the informed consent document;
- •Be able to stick to follow-up visit plan and other requirements in the agreement.
排除标准
- •Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;
- •Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%;
- •Significant cardiovascular anomalies according to any of the following definition: New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block, etc.
- •Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;
- •Severe physical or mental diseases;
- •Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection);
- •Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy;
- •History of allergy to chemical compound consisting of chemical and biologic substances resembling cell therapy;
- •Having received immunotherapy and developed irAE level greater than Level 3;
- •Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded);
- •Females in pregnancy or lactation;
- •History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy;
- •Researchers considering the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.
研究组 & 干预措施
Signal Switch Receptor Modified TIL
2x10^8-1x10^10 in vitro expanded autologous PD-1 or TGF-β signal switch receptor modified TIL (GC201 TIL) will be infused i.v. to patients with advanced gynecologic tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
干预措施: Signal Switch Receptor Modified TIL (Biological)
结局指标
主要结局
Adverse Events (AE)
时间窗: Up to 6 months
To characterize the safety profile of Signal Switch Receptor Modified TIL (GC201 TIL) in patients with advanced gynecologic tumors as assessed by incidence of adverse events related to GC201 TIL infusion.
Disease Control Rate (DCR）
时间窗: Up to 36 months
Percentage of patients that meet CR, PR and SD criteria set in this study according to RECIST v1.1： DCR (proportion of patients) = # with CR + # with PR + # with SD / # with CR + # with PR + # with SD + # with PD.
Progression-Free Survival (PFS)
时间窗: Up to 36 months
The time length between GC201 TIL infusion and confirmed subsequent disease progression according to RECIST 1.1
Objective Response Rate (ORR)
时间窗: Up to 36 months
Proportion of patients with response per Response Evaluation Criteria in Solid Tumors (RECIST v1.1): ORR (proportion of patients) = # with CR + # with PR / # with CR + # with PR + # with SD + # with PD. ( Except baseline evaluation within 28 days before TIL infusion，PET/CT scan will be performed at 6 weeks after GC201 TIL infusion, and than every 6 weeks for 6 months, and then every 6 months after that for up to 3 years)
Duration of Response (DOR)
时间窗: Up to 36 months ]
The time length between the first confirmed objective response per RECIST 1.1 to the treatment and the subsequent disease progression per RECIST 1.1
Overall Survival (OS)
时间窗: Up to 36 months ]
The length of time from the date of the start of GC201 TIL treatment that the patients are still alive
次要结局
- Change in Quality of Life(Up to 36 months)